DiversiTrials reposted this
🚨 MUST READ: The FDA Diversity Action Plan (DAP) is BACK! 🚨 🌍 Hello, Bonjour, Hola, Marhaba! For those who may have missed the memo, the FDA Diversity Action Plan (DAP) is officially back online. 📢 Given the agency’s recent workforce challenges, I propose that Hadi Danawi, PhD, MPH د. هادي ضناوي—alongside MENASA GROUP, Rethix & DiversiTrials—take the lead on these crucial DAP reviews. 👉 Why does this matter? This isn’t just another policy update. It’s a game-changer for clinical trial diversity, representation, and equitable healthcare. As someone who has been deeply involved in shaping the FDA DAP—including providing significant feedback to the FDA, engaging in OMB Directive 15, and advocating for its reinstatement under the Trump Administration and HHS—this is a HUGE WIN. 👏 YES, you’re welcome! Now, let’s get to work. 💬 What’s your take? How should we hold sponsors accountable under the reinstated DAP? Drop your thoughts below! ⬇️ #FDA #DiversityInClinicalTrials #ClinicalResearch #HealthEquity #RegulatoryAffairs #MENASAGroup #DiversiTrials